Millions unite for diabetes awareness on World Diabetes Day 2010

Starting today, people from all corners of the world are uniting together for three days of celebration to put diabetes firmly in the public spotlight. World Diabetes Day is the best opportunity there is to draw attention to the silent killer that is diabetes.

Celebrated every year on 14 November, World Diabetes Day was initiated in 1991 by the International Diabetes Federation (IDF) and the World Health Organization in response to growing concerns about the escalating health threat that diabetes poses to the global community. An official United Nations Day since the passage of UN Resolution 61/225 in 2006, World Diabetes Day draws attention to issues of paramount importance to the diabetes world and keeps diabetes firmly in the public spotlight. It is represented by the blue circle - the global symbol of diabetes.

Diabetes is a leading threat to global health and development. According to IDF, the disease now affects over 300 million people worldwide and will cost the global economy at least US$376 billion in 2010, or 11.6% of total world healthcare expenditure. A further 344 million people are at risk of developing type 2 diabetes, the most common form of the disease. If nothing is done to reverse the epidemic, IDF predicts that by 2030, 438 million people will live with diabetes at a cost projected to exceed US$490 billion.

"Ninety years after the discovery of insulin and four years after UN Resolution 61/225, the number of people with diabetes continues to grow at a staggering rate. In every country and in every community worldwide, we are losing the battle against this cruel and deadly disease," said IDF President Jean Claude Mbanya.

Faced with these alarming numbers, World Diabetes Day aims to establish access to diabetes education as a right for all people with diabetes, to promote greater awareness of the risk factors and warning signs of diabetes, and encourage best-practice sharing in diabetes prevention.

This year sees the second of a five-year campaign (2009-2013) that addresses the growing need for diabetes education and prevention programmes throughout the world. The theme for World Diabetes Day 2010 is "Let's take control of diabetes. Now". In keeping with this theme, IDF has developed a special web application - the Blue Circle Test - to showcase the risk factors for type 2 diabetes and highlight the positive actions that individuals can take to help prevent the disease.

FINALLY, GLOBAL POLITICAL WILL FOR A PERMANENT SOLUTION

The world is finally waking up to the threat of diabetes and other non-communicable diseases (NCDs). On May 13 this year, the UN General Assembly voted unanimously for UN Resolution 64/265 to hold a UN High Level Summit on Non-Communicable Diseases in September 2011. A similar Summit on HIV/AIDS in 2001 proved a turning point for the fight against that disease. "The UN Summit will bring heads of state, government representatives, NGOs and public health experts together to discuss the global threat and commit to the global response required for diabetes and other NCDs," Ann Keeling, IDF Chief Executive Officer said. "World Diabetes Day provides an ideal platform to disseminate and promote IDF's key messages and objectives for the UN Summit," Ms Keeling added.

To mark World Diabetes Day this year, IDF is coordinating a programme of work - called the Diabetes Roadmap - that will produce and package arguments, evidence and solutions to ensure the UN Summit translates into real change for the millions of people with diabetes worldwide.

A Call to Action on Diabetes will be launched on November 14 in the diabetes epicentre of the world: China. China has 92.4 million adults with diabetes (1 in every 10 adults). A Call to Action is the central advocacy tool for the global diabetes community in the lead up to the UN Summit, bringing the global diabetes epidemic to the attention of world leaders, and guide and secure action, commitment, support and resources for diabetes. The document will be unveiled as part of World Diabetes Day festivities at the iconic Great Hall of the People in Beijing. New data on how much diabetes is costing the Chinese economy and society will also be announced.

Celebrations will extend from China to various countries in the world, with famous landmarks and monuments once again lighting up in blue for diabetes awareness. More than 500 iconic buildings in over 60 countries will be illuminated, including Table Mountain in South Africa, Christ the Redeemer in Brazil, the Brandenburger Tor in Germany, and Niagara Falls in Canada. Activities such as mass walks for diabetes and aerobics will be held in conjunction with these lightings, to demonstrate the importance of a healthy lifestyle to help take control of this epidemic.

"Our global diabetes champions will literally bring diabetes to light on World Diabetes Day. No matter where we are, it's our efforts that will make World Diabetes Day a truly global success," said Prof Mbanya.

"The time to act for diabetes is now."

For more information on World Diabetes Day visit:
http://www.worlddiabetesday.org

About The International Diabetes Federation
The International Diabetes Federation (IDF) is the global advocate for more than 300 million people with diabetes worldwide. It represents over 200 diabetes associations in more than 160 countries. Its mission is to promote diabetes care, prevention and a cure worldwide. IDF is in official relations with the World Health Organization and associated with the United Nations Department of Public Information.

The World Diabetes Day campaign is supported by the following official partners: Abbott Diabetes Care, AstraZeneca, Becton Dickinson, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, LifeScan, Eli Lilly, Medtronic, Merck Sharp & Dohme (MSD), Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, and Takeda.

For more information on the International Diabetes Federation visit: http://www.idf.org.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...